Table 2. Associations between survival, culture cycle time and demographic and treatment variables.
| No. | Median culture cycle time in days (95% CI) | Cycle ⩽10 days, n (%) | Cycle >10 days, n (%) | Percentage alive at 1 year (95% CI) a | Median survival (95% CI) in months a | |
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| <30 | 8 | 11.4 (4.5–17.2) | 4 (50%) | 4 (50%) | 45% (11–75%) | 9.5b |
| 30–49 | 22 | 10.9 (7.6–19.5) | 11 (50%) | 11 (50%) | 62% (37–79%) | 30.7 (5.1–66.5) |
| 50–59 | 12 | 12.0 (6.7–15.8) | 5 (42%) | 7 (58%) | 42% (15–67%) | 9.1 (3.3–13.7) |
| 60–69 | 14 | 9.9 (8.8–23.0) | 7 (50%) | 7 (50%) | 14% (2–37%) | 7.3 (2.1–8.8) |
| 70+ | 14 | 11.7 (8.2–31.0) | 7 (50%) | 7 (50%) | 21% (5–45%) | 2.6 (1.2–10.9) |
| P=0.9 | P=0.99 | P=0.002+ | ||||
| Gender | ||||||
| Male | 41 | 12.2 (8.9–17.5) | 18 (44%) | 23 (56%) | 39% (24–54%) | 8.2 (3.6–12.4) |
| Female | 29 | 9.8 (8.3–13.3) | 16 (55%) | 13 (45%) | 36% (19–54%) | 8.9 (4.8–13.7) |
| P=0.4 | P=0.4 | P=0.9+ | ||||
| Tumour type | ||||||
| Glioblastoma | 43 | 9. 8 (9.1–12.6) | 23 (53%) | 20 (47%) | 28% (16–42%) | 7.6 (4.7–9.1) |
| Astrocytoma/oligodendroglioma | 13 | 16.0 (13.0–27.5) | 2 (15%) | 11 (85%) | 64% (30–85%) | 66.4 (9.5–104.1) |
| Medulloblastoma | 6 | 9.9 (3.3–37.8) | 3 (50%) | 3 (50%) | 67%b | —c |
| Metastatic melanoma | 8 | 6.7 (3.1–32.4) | 6 (75%) | 2 (25%) | 31% (5–64%) | 3.7 (0.1–12.4) |
| P=0.06 | P=0.04 | P=0.0004+ | ||||
| Radiotherapy | ||||||
| Yes | 37 | 13.3 (9.8–18.7) | 13 (35%) | 24 (65% | 51% (34–66%) | 12.1 (8.5–18.4) |
| No | 24 | 9.6 (7.3–14.0) | 14 (58%) | 10 (42%) | 15% (4–33%) | 2.6 (1.5–7.2) |
| Unknown | 9 | 8.1 (4.9–24.2) | 7 (78%) | 2 (22%) | 46% (11–76%) | 9.6 (0.7–16.1) |
| P=0.2 | P=0.04 | P=0.0003+ | ||||
+Log rank.
a
Calculated using life table methods.
b
Numbers too small for calculation.
c
Survival curve did not go below 50%.